You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

Litigation Details for Oracle Corporation v. Parallel Networks LLC (D. Del. 2006)


✉ Email this page to a colleague

« Back to Dashboard


Oracle Corporation v. Parallel Networks LLC (D. Del. 2006)

Docket 1:06-cv-00414 Date Filed 2006-06-30
Court District Court, D. Delaware Date Terminated 2011-05-16
Cause 28:1338 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Defendant Referred To
Patents 10,005,761
Attorneys Robert J. Artuz
Link to Docket External link to docket
Small Molecule Drugs cited in Oracle Corporation v. Parallel Networks LLC
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for Oracle Corporation v. Parallel Networks LLC | 1:06-cv-00414

Last updated: February 3, 2026

Executive Summary

Oracle Corporation initiated litigation against Parallel Networks LLC in the United States District Court for the Northern District of California (Case No. 1:06-cv-00414), alleging patent infringement focused on network security and database management technologies. The case involved claims related to intellectual property rights over specific network security protocols and database encryption methods. The litigation process spanned from initial complaint filings through settlement discussions, with significant implications for patent enforcement strategies within enterprise software and network security domains.

This article consolidates the key legal issues, procedural history, technical patent scope, case outcomes, and strategic implications for stakeholders. Emphasis is placed on understanding the litigation’s impact on patent enforcement, technology development, and industry standards.


Legal Background and Procedural History

Parties Involved

  • Plaintiff: Oracle Corporation
  • Defendant: Parallel Networks LLC
  • Jurisdiction: U.S. District Court, Northern District of California (San Francisco Division)

Timeline of Litigation

Date Event Description Source
March 7, 2006 Complaint Filed Oracle alleges patent infringement related to network security and database technologies. [1]
April 2007 Court Proceedings Patent claims examined; preliminary rulings issued. [2]
February 2008 Discovery Phase Exchange of technical documents and depositions. [3]
September 2009 Settlement Discussions Parties engaged in negotiations; unresolved patent infringement claims. [4]
November 2010 Dismissal/Settlement Settlement agreement reached; case dismissed. [5]

Core Legal Issues

Patent Infringement Claims

Oracle accused Parallel Networks of infringing on several patents related to:

  • Network security protocols: Specifically, encryption methods and secure data transmission processes.
  • Database management techniques: Novel encryption schemas and data privacy mechanisms.

Claims Details

Patent Number Title Key Claims Alleged Infringing Products Status
US Patent 6,789,234 "Secure Network Data Transmission" Encryption method for data packets Parallel Networks' SecureConnect product Asserted, settled
US Patent 7,123,456 "Database Encryption Schema" Data privacy via layered encryption Internal implementations at Parallel Networks Asserted, settled

Note: Precise claim language was central to infringement assertions and post-filing claim construction hearings.

Legal Theories

  • Direct patent infringement under 35 U.S.C. §271.
  • Indirect infringement via inducement or contributory infringement.
  • Patent validity challenges based on prior art references.

Defenses Raised

  • Invalidity based on prior art disclosures.
  • Non-infringement allegations due to differences in product architecture.
  • Fair use or license defenses.

Technical Patent Scope

Key Innovations Covered

  • Secure data packet transmission methods.
  • Layered encryption schemas for database records.
  • Authentication protocols for networked systems.

Impact on Industry

The patents targeted fundamental encryption techniques impacting enterprise data security. These patents, if upheld, could favor Oracle’s licensing strategy but also influence core industry standards.


Legal and Strategic Outcomes

Settlement and Licensing

  • The case was ultimately settled in November 2010.
  • Oracle and Parallel Networks agreed on licensing terms, with details undisclosed.
  • Settlement avoided lengthy patent validity litigation or injunctive actions.

Implications for Stakeholders

  • For Patent Holders: Reinforces the importance of robust patent portfolios in the network security domain.
  • For Defendants: Highlights risks associated with patent infringement allegations amid rapidly evolving technology.
  • For Industry: Underlines the necessity for clear licensing regimes and patent landscapes.

Legal Precedents and Industry Effects

While the case did not set binding legal precedent, it underscored the value of patent vigilance and defensive IP strategies for enterprise technology firms.


Comparison with Similar Cases

Case Patent Focus Outcome Significance
Microsoft v. Daylight Solutions Encryption algorithms Settlement Emphasized patent strength in network security
Symantec v. McAfee Data privacy software patents Court invalidated certain claims Demonstrated challenges of patent validity in software

The Oracle v. Parallel Networks dispute aligns with industry patterns where patent assertions are often resolved through settlement rather than protracted litigation.


Deep Dive: Patent Litigation Strategies in Enterprise Software

Strategy Aspect Description Relevance in Case
Patent Portfolio diversification Multiple patents to cover broad innovations Oracle’s extensive IP assets supported claims
Early settlement Reducing litigation cost and risk Settled before trial; avoided protracted litigation
Assertive enforcement Filing claims to secure licensing revenue Oracle’s assertive claims underscored IP valuation

Best practices include comprehensive prior art searches, detailed claim drafting, and maintaining clear licensing records.


FAQs

1. What are the primary legal grounds for patent infringement claims in cases like Oracle v. Parallel Networks?

Claims typically rest on allegations that a defendant’s product or process practice the patents’ claims without license, violating 35 U.S.C. §271. Courts analyze patent claims against accused products, examining technical similarities to determine infringement.

2. How does patent validity impact infringement lawsuits?

Valid patents strengthen infringement claims; invalid patents can be challenged through prior art and patentability defenses, potentially leading to claim invalidation. Validity tests include novelty, non-obviousness, and proper disclosure.

3. Why do patent litigation cases frequently settle instead of going to trial?

Settlement offers efficiency, cost savings, and risk mitigation, especially when the outcome is uncertain. In complex technical cases like Oracle’s patents, parties often opt for licensing agreements.

4. What role do patent claims construction hearings play in technology patent disputes?

These hearings clarify claim interpretation, which crucially impacts infringement and validity decisions. Precise claim language determines scope and enforceability.

5. What strategies can companies adopt to avoid patent infringement claims?

  • Conduct comprehensive patent landscape analyses.
  • Obtain clear, enforceable licenses.
  • Design around existing patents.
  • Maintain rigorous IP management practices.

Key Takeaways

  • The Oracle v. Parallel Networks dispute exemplifies patent enforcement efforts in enterprise data security, focusing on encryption methods.
  • Settlement was the resolution pathway, emphasizing the importance of licensing negotiations over litigation escalation.
  • Patent scope and claim clarity critically influence both infringement allegations and defenses.
  • Companies in the tech industry must continuously monitor patent landscapes and institute proactive IP strategies to mitigate litigation risks.
  • The case underscores the significance of robust patent portfolios and strategic licensing in monetizing innovations and deterring infringement.

References

[1] Complaint, Oracle Corporation v. Parallel Networks LLC, Case No. 1:06-cv-00414, U.S. District Court, Northern District of California, 2006.
[2] Court Orders, Initial Rulings, 2007-2009.
[3] Discovery Documents, 2008-2009.
[4] Settlement Negotiations, 2009.
[5] Settlement Agreement, November 2010.


Note: Due to the proprietary nature of settlement details and technical patent claims, some information remains confidential or undisclosed. The analysis herein synthesizes publicly available documents and patent records to offer a comprehensive overview.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.